Firstly, vaccines against known antigens or epitopes which are peptide-based, such as PR1, a 9-mer peptide of proteinase-3 with high predicted binding and Wilm's Tumor (WT)-1 are shown to lead to specific T-cell responses in myeloid leukemia patients [19]. This evidence concerns the gene TMEM37 and myeloid leukemia.